Explore

Trendline Trendline
Fourth Power Develops High-Temperature Thermal Energy Storage System Using Graphite Bricks and Liquid Tin

Fourth Power Develops High-Temperature Thermal Energy Storage System Using Graphite Bricks and Liquid Tin

Fourth Power Develops High-Temperature Thermal Energy Storage System Using Graphite Bricks and Liquid Tin
Rapid Read Rapid Read
Anthro Energy Breaks Ground on First-of-its-Kind U.S. Battery Materials Factory in Kentucky

Anthro Energy Breaks Ground on First-of-its-Kind U.S. Battery Materials Factory in Kentucky

Anthro Energy has commenced construction on a pioneering battery materials factory in Louisville, Kentucky. This facility is set to be the first large-scale, U.S.-owned and operated plant dedicated to producing advanced electrolytes for lithium-ion batteries. With an anticipated annual output capable of supporting up to 25 gigawatt-hours (GWh) of batteries, the factory is expected to open in late 2027 and produce approximately 12,000 metric tons of polymer electrolyte annually. The project, valued at over $42 million, received significant federal backing, including a $24.9 million award from the U.S. Department of Energy through the Biden administration’s Infrastructure Investment and Jobs Act, and $18.4 million in federal investment tax credits via the Inflation Reduction Act’s 48C program. This initiative is projected to create 110 permanent manufacturing and technical jobs, alongside nearly 390 construction jobs.
Trendline Trendline
DeltaX Establishes $141 Million North American Headquarters in Walton County, Georgia, Creating 250 Jobs

DeltaX Establishes $141 Million North American Headquarters in Walton County, Georgia, Creating 250 Jobs

DeltaX Establishes $141 Million North American Headquarters in Walton County, Georgia, Creating 250 Jobs
Trendline Trendline
Shoals Technologies Completes Tennessee Manufacturing Relocation Amid Record $801 Million Solar Order Backlog

Shoals Technologies Completes Tennessee Manufacturing Relocation Amid Record $801 Million Solar Order Backlog

Shoals Technologies Completes Tennessee Manufacturing Relocation Amid Record $801 Million Solar Order Backlog
Trendline Trendline
Apollo Atomics Secures $31 Million to Advance Compact Nuclear Reactor Technology

Apollo Atomics Secures $31 Million to Advance Compact Nuclear Reactor Technology

Apollo Atomics Secures $31 Million to Advance Compact Nuclear Reactor Technology
Trendline Trendline
Solrite Launches Zero-Down Solar-Plus-Storage Program for Illinois Homeowners

Solrite Launches Zero-Down Solar-Plus-Storage Program for Illinois Homeowners

Solrite Launches Zero-Down Solar-Plus-Storage Program for Illinois Homeowners
Trendline Trendline
Form Energy Receives $5.7 Million Massachusetts Tax Credit for Climate-Tech Initiatives

Form Energy Receives $5.7 Million Massachusetts Tax Credit for Climate-Tech Initiatives

Form Energy Receives $5.7 Million Massachusetts Tax Credit for Climate-Tech Initiatives
AP News AP News
Takeaways from a story on the US, Australia and others turning to Brazil for rare earth minerals

Takeaways from a story on the US, Australia and others turning to Brazil for rare earth minerals

Brazil is becoming a key player in the rare earth minerals market
Rapid Read Rapid Read
Ultragenyx Secures First Gene Therapy Approval for Glycogen Storage Disease Type Ia

Ultragenyx Secures First Gene Therapy Approval for Glycogen Storage Disease Type Ia

Ultragenyx has received accelerated approval from the U.S. Food and Drug Administration (FDA) for its first gene therapy, pariglasgene brecaparvovec-opnr, now branded as Genglycos. This therapy is designed to treat glycogen storage disease type Ia (GSDIa) in adults and children over the age of eight. GSDIa is a rare genetic disorder caused by a deficiency of the G6PC enzyme, which is crucial for releasing glucose from the liver. Genglycos, a one-time AAV8 gene therapy, aims to deliver a functional G6PC gene to the liver, restoring the enzyme and helping to stabilize blood sugar levels. The approval follows a successful late-stage study where Genglycos significantly reduced the daily cornstarch intake required by patients, a common treatment for GSDIa.
Rapid Read Rapid Read
Ultragenyx Receives FDA Approval for First Gene Therapy, Genglycos, for Glycogen Storage Disease Type Ia

Ultragenyx Receives FDA Approval for First Gene Therapy, Genglycos, for Glycogen Storage Disease Type Ia

Ultragenyx has received accelerated FDA approval for Genglycos (pariglasgene brecaparvovec-opnr), its first gene therapy, for the treatment of glycogen storage disease type Ia (GSDIa). This approval specifically targets adults and children over the age of 8 years who suffer from GSDIa, a rare genetic disorder caused by a deficiency of the G6PC enzyme, which is crucial for releasing glucose from the liver into the bloodstream. The condition leads to life-threatening hypoglycemia and other complications. Genglycos is a one-time AAV8 gene therapy designed to deliver a functional G6PC gene to the liver, aiming to restore the deficient enzyme and stabilize blood sugar levels during fasting. The approval follows a successful late-stage GlucoGene study, where the treatment significantly reduced daily cornstarch intake in patients compared to placebo. This marks Ultragenyx's fifth FDA approval and includes a valuable priority review voucher.
Trendline Trendline
LG Energy Solution Initiates Production at Michigan Battery Plant, Boosting U.S. Energy Storage and EV Battery Supply

LG Energy Solution Initiates Production at Michigan Battery Plant, Boosting U.S. Energy Storage and EV Battery Supply

LG Energy Solution Initiates Production at Michigan Battery Plant, Boosting U.S. Energy Storage and EV Battery Supply
AP News AP News
The US and others turn to Brazil for rare earths, raising environmental concerns

The US and others turn to Brazil for rare earths, raising environmental concerns

Brazil is becoming a key global battleground for rare earth minerals that are crucial for renewable energy and technology